Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of pernambuco, Brazil: A case-control study

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 3, 2010, Pages 271-277

  Gelenske, Thais ^a   E Farias, Francisco Alfredo Bandeira ^b   De Alencar Ximenes, Ricardo Arraes ^b,c   De Melo, Heloísa Ramos Lacerda ^b,c   De Fátima Pessoa Militão De Albuquerque, Maria ^b,d   De Carvalho, Érico Higino ^a   De Medeiros Barros, Zoraya ^b   Diniz, George Tadeu Nunes ^d   De Barros Miranda Filho, Demócrito ^b  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BIOLOGICAL MARKER; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSULINEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BRAZIL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953757295     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0065     Document Type: Article

References (32)

1. Carr A , Samaras K , Burton S , et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistence in patients receiving HIV protease inhibitiors. AIDS 1998 ; 12: F51-F58.
2. Carr A. HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. AIDS 2003 ; 17 (Suppl 1): S141-S148.
3. Chen D , Misra A , Garg A. Lipodystrophy in human immunodefi ciency virus-infected patientes. J Clin Endocrinol Metab 2002 ; 87: 4845-4856.
4. Blanco F , Carr A. Lipodystrophy syndrome: Diagnostic, clinic and therapeutic aspects. AIDS 2001 ; 3: 98-105.
5. Fernandes , A.P.M. , Saches R.S. , Mill , J. , et al. Síndrome da lipodystrophy associada com a terapia anti-retroviral em portadores do HIV: considerações para os aspectos psicossociais. Rev Lat Am Enfermagem, 2007 , 15: 1041-1045.
6. Pontes LCR , Carvalho LR , Souza LR , et al. Lipid profile and body composition of HIV-1 infected patients treated with highly active antiretroviral therapy. J Venom Animals Toxins Incl Trop Dis 2005 ; 11: 143-159.
7. Pontes-Cardoso LCR , Souza LR , Peraçoli MTS , et al. Cytokine profile and clinical metabolic alterations in HIV-1 infected individuals with and without lipodystrophy. J Venom Animals Toxins Incl Trop Dis 2007 ; 13: 509-526.
8. Ronchini KROM , Duarte AJS , Casseb JSR , Gidlund M. Cardiovascular complications and increased levels of circulating modifi ed low density lipoprotein in HIV patients and patients with lipodystrophy. Braz J Med Biol Res 2004 ; 37: 119-122.
9. Santos CP , Felipe YX , Braga PE , et al. Self-perception of body changes in persons living with HIV/aids: Prevalence and associated factors. AIDS 2005 ; 19 (Suppl 4): S14-S21.
10. Diehl LA , Dias JR , Paes ACS , et al. Prevalência de lipodistrofi a associada ao HIV em pacientes ambulatoriais brasileiros: Relação com síndrome metabólica e fatores de risco cardiovascular. Arq Bras Endocrinol Metab 2008 ; 52: 658-667.
11. Guimarães MMM , Greco DB , Júnior O AR , et al. Distribuição da gordura corporal e perfi s lipídico e glicêmicode pacientes infectados pelo HIV. Arq Bras Endocrinol Metab 2007 ; 51: 42-51.
12. Lichtenstein K , Ward JD , Moorman AC , et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001 ; 15: 1389-1398.
13. Carr A , Emery S , Law M , and The HIV Lipodystrophy Case Definition Study Group. An objective case Definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003 ; 61: 726-735.
14. Fessel WJ , Follansbee SE , Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: Implications for pathogenesis of fat redistribution. AIDS 2002 ; 16: 1785-1789.
15. Friedwald WT , Levy R , Fredrickson DS. Estimation of the concentration pf low lipoprotein cholesterol in plasma without us of the preparative ultracentrifuge. Clin Chem 1972 ; 18: 499-504.
16. Bergersen BM , Sandvik L , Brunn JN. Body composition changes in 308 Norwegian HIV-positive patients. Scand J Infect Dis 2004 ; 36: 186-194.
17. Joly V , Flandre P , Meifreddy V , et al. Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: Results of a substudy from comparative trials. AIDS , 2002 ; 16: 2447-2454.
18. Sàves M , Raffi F , Capeau J , et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodefi ciency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002 ; 34: 1396-1405.
19. Nolan D , Hammond E , James I , et al. Contribution of nucleoside- analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003 ; 8: 617-626.
20. Bergersen BM , Sandvik L , Brunn JN. Lipoatrophy men 44 months after the diagnosis of lipoatrophy are less lipoatrophy but more hypertensive. HIV Med 2005: 6: 260-267.
21. Heath K , Chan KJ , Singer J , et al. Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002 ; 31: 1016-1020.
22. Dube MP , Komarow L , Mulligan K , et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfi navir or efavirenz or both plus dual nucleosides: Dual x-ray absorptiometry results from A5003S, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007 ; 45: 508-514.
23. Brinkman K , Smeitink JA , Romijn JA , et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy- related lipodystrophy. Lancet 1999 ; 354: 1112-1115.
24. Brasil Ministério da Saúde , Secretaria de Vigilância e Saúde , Programa Nacional de DST e Aids. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2007/2008: Documento preliminar, 2007. www.saude.rio.rj.gov. br/media/dstaids-consenso-adulto-2008.pdf/. Accessed June 5, 2008.
25. World Health Organization. HIV/AIDS Programme. Antiretroviral Therapy for HIV Infection in Adult an Adolescents: Recommendations for a Public Health Approach, 2006 revision. www.who.int/hiv/pub/guidelines/artadultguidelines.pdf/. Acessed September 10, 2009.
26. Carr A , Samaras K , Thorisdottir A , et al., Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipaemia, and diabetes mellitus: A cohort study. Lancet 1999 ; 353: 2093-2099.
27. Lichtenstein KA , Delaney KM , Armon C , et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr 2003 ; 32: 48-56.
28. Shlav JC , Bartsch G , Pehg G , et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007 ; 44: 506-517.
29. Bradbury , R.A. , Samaras , K. Antiretroviral therapy and the human immunoDeficiency virus - improve survival, but at what cost? Diabetes Obes Metab , 2008 , 10: 441-450.
30. Thiébaut R , Daucourt V , Mercie P , et al. Lipodystrophy, metabolic disorders, and human immunoDeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000 ; 31: 1482-1487.
31. National Cholesterol Education Program (NCEP) Expert P anel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation,and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation 2002 ; 106: 3143-3421.
32. Grundy SM. Obesity, metabolic syndrome and cardiovascular disease. J Clin Endocrinol Metab 2004 ; 89: 2595-2600.